| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
| ln Vivo |
Ethambutol hydrochloride can be used in animal modeling to produce a high uric acid model.
|
|---|---|
| References | |
| Additional Infomation |
Ethambutol hydrochloride is an antibacterial prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of active tuberculosis (TB) of the lungs. (Active TB is also called TB disease.)
TB can be an opportunistic infection (OI) of HIV. Ethambutol Hydrochloride is the hydrochloride salt form of ethambutol, an ethylenediamine derivative with antibacterial activity, specifically effective against mycobacteria. Although the exact mechanism of action of ethambutol hydrochloride is unknown, ethambutol hydrochloride inhibits the transfer of mycolic acids into the cell wall of bacteria, which impedes bacterial cell growth. This agent may also interfere with RNA synthesis or inhibit other cell metabolism, thereby preventing cell multiplication and causing cell death. An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) |
| Exact Mass |
276.137
|
|---|---|
| CAS # |
1070-11-7
|
| Related CAS # |
Ethambutol;74-55-5
|
| PubChem CID |
14051
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
345.3ºC at 760 mmHg
|
| Melting Point |
198-200°C
|
| Flash Point |
113.7ºC
|
| Vapour Pressure |
3.35E-07mmHg at 25°C
|
| LogP |
2.093
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
16
|
| Complexity |
109
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC[C@@H](CO)NCCN[C@@H](CC)CO.Cl.Cl
|
| InChi Key |
AUAHHJJRFHRVPV-BZDVOYDHSA-N
|
| InChi Code |
InChI=1S/C10H24N2O2.2ClH/c1-3-9(7-13)11-5-6-12-10(4-2)8-14;;/h9-14H,3-8H2,1-2H3;2*1H/t9-,10-;;/m0../s1
|
| Chemical Name |
(2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol;dihydrochloride
|
| Synonyms |
Ethambutol Hydrochloride Ethambutol HCL 4878
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~360.71 mM)
H2O : ≥ 50 mg/mL (~180.36 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (360.71 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00002343 | COMPLETED | Drug: Ethambutol hydrochloride Drug: Rifabutin |
HIV Infections Mycobacterium Avium-Intracellulare Infection |
Pharmacia | Phase 4 | |
| NCT01048697 | COMPLETEDWITH RESULTS | Drug: Ethambutol | Obesity Tuberculosis |
Texas Tech University Health Sciences Center | 2010-01 | Phase 4 |
| NCT01994460 | UNKNOWN STATUS | Drug: Linezolid Drug: Ethambutol |
Pulmonary Tuberculosis Without Resistance to Rifampicin | Seoul National University Hospital | 2014-01 | Phase 2 |
| NCT05966688 | COMPLETED | Drug: SPR720 Drug: Azithromycin Drug: Ethambutol |
Healthy Volunteers | Spero Therapeutics | 2023-08-04 | Phase 1 |
| NCT04972903 | UNKNOWN STATUS | Pulmonary Tuberculosis |
Institut National de la Santé Et de la Recherche Médicale, France |
2021-08 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
